Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA-P for Post-discharge Malaria Chemoprevention in Severe Anemia
NCT02671175Phase 3Completed
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of dihydroartemisinin in malaria (2 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: All-cause deaths or all-cause re-admissions at 26 weeks. Started May 2016; status: completed.
02
Drugs
dihydroartemisinin
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02671175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671175.